Although this dose of romosozumab (30 mg/kg, twice monthly) has not been evaluated in humans, another sclerostin antibody was administered at 20 mg/kg or 40 mg/kg monthly up to 6 months in patients with osteogenesis imperfecta and appeared to be safe in subjects with osteogenesis imperfecta [42]. The gene discussed is SOST; the disease is osteogenesis imperfecta.